IL17A and tuberculosis: In order to investigate the ability of the novel TB vaccine MVA85A to further boost the enhanced IL-17 responses observed following BCG + CT administration i.n., Balb/c mice were vaccinated with BCG±CT i.n. followed 10 weeks later by MVA85A i.n.